1 day Ago By Defense World Staff
Renaissance Technologies LLC grew its stake in Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA – Free Report ) by 65.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission.
The institutional investor owned 114,654 shares of the company’s stock after purchasing an additional 45,200 shares during the period. Renaissance Technologies LLC owned about 0.20% of Ginkgo Bioworks worth $1,126,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. FNY Investment Advisers LLC boosted its position in Ginkgo Bioworks by 125.6% in the fourth quarter.
FNY Investment Advisers LLC now owns 75,966 shares of the company’s stock valued at $745,000 after buying an additional 42,298 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Ginkgo Bioworks in the 4th quarter valued at $199,000. KBC Group NV acquired a new stake in shares of Ginkgo Bioworks during the 4th quarter valued at $31,000.
Forbes J M & Co. LLP grew its position in Ginkgo Bioworks by 461.4% during the 4th quarter.
Forbes J M & Co. LLP now owns 701,732 shares of the company’s stock worth $6,891,000 after acquiring an additional 576,732 shares during the last quarter. Finally, Palumbo Wealth Management LLC acquired a new position in Ginkgo Bioworks in the 4th quarter worth about $144,000.
78.63% of the stock is owned by institutional investors. Ginkgo Bioworks Trading Down 8.
1 % Ginkgo Bioworks stock opened at $7.37 on Wednesday. The company has a market capitalization of $427.
71 million, a PE ratio of -0.56 and a beta of 1.34.
The stock has a 50-day moving average price of $7.45 and a two-hundred day moving average price of $9.15.
Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.00 and a 12 month high of $41.
20. About Ginkgo Bioworks Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum.
It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. See Also Five stocks we like better than Ginkgo Bioworks Why Understanding Call Option Volume is Essential to Successful Options Trading Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet About the Markup Calculator Coca-Cola Company Stock Can Bubble to New Highs This Year Business Services Stocks Investing 3 Stocks Lifting 2025 Guidance Despite Market Jitters Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc.
( NYSE:DNA – Free Report ). Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter .
.
